Abstract:Objectives To investigate the effect of calcium antagonists (CCB) and statins on carotid plaques and plasma inflammatory mediators, so as to learn the possible mechanism of their anti-atherogenic effect. Methods This is a cross-sectional study. Laboratory tests and carotid ultrasound examination were performed in patients with essential hypertension. All patients were divided into three groups, who were treated with CCB or statins monotherapy or CCB and statins combination therapy respectively. Laboratory parameters included plasma low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), high-sensitivity C-reactive protein (hsCRP), the medulla metalloproteinase 9 (MMP9) and the lipoprotein-associated phospholipase A2 (Lp-PLA2). Correlation analysis was performed between the three groups. Results Baseline conditions Total 150 patients with essential hypertension were enrolled in, among them 78 (52.0%) were male and 72 (48.0%)were female. Thirty-nine patients complicated with diabetes mellitus, accounting for 26.0%. Thirty-six patients complicated with hyperlipidaemia, accounting for 16.0%. The mean age was 59.06 years and the mean blood pressure was 140.21/84.73 mm Hg. Comparison Analysis of Plasma Lipids and Inflammatory Parameters Level Compared with patients who were not treated with statins, patients treated with statins had lower total cholesterol and LDL-C levels. The plasma levels of Lp-PLA2, MMP9 and hsCRP were similar in patients treated with different drugs, the difference was not statistically significant. Correlation Analysis between Inflammatory Status and Carotid Atherosclerosis Pearman correlation analysis showed that Lp-PLA2 content was linearly correlated with hsCRP levels, the correlation coefficient was 0.282, p=0.001. But MMP9 content was not correlated with hsCRP levels, the correlation coefficient was 0.107, p=0.213. Compared with patients without carotid plaques, patients with soft carotid plaques had higher plasma content of hsCRP and Lp-PLA2, the difference was statistically significant showed by ANOVA analysis. MMP9 content was relatively lower in patients with soft carotid plaque, but the difference was not statistically significant. Conclusions 1. Plasma LP- PLA2 content, which was positively correlated with plasma hsCRP level, can reflect the body's inflammatory state better than that of MMP9. 2. Patients with soft carotid plaques had higher plasma level of LP-PLA2, which suggested that the LP-PLA2 level can reflect the stability of plaques. 3. The difference of inflammatory parameters in different groups was not statistically significant.

Effects of rosuvastatin on hypertension with carotid atherosclerosis and its influence on peripheral macrophage polarization

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Effect of Rosuvastatin on the Change of Th1/Th2 Subsets in Coronary Heart Disease with Diabetes

Rosuvastatin Reverses Hypertension-Induced Changes in the Aorta Structure and Endothelium-Dependent Relaxation in Rats Through Suppression of Apoptosis and Inflammation.

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Effects of Different Doses of Rosuvastatin on High-sensitivity C-reactive Protein(hs-CRP) and Interleukin-6 (IL-6) in Patients with Acute Coronary Syndrome.

The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus: Rationale and Design of RosCal Study

Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins.

Effect of nifedipine controlled released tablet and atorvastatin on carotid intimamedia thickness and vascular endothelial function in patients with hypertension

Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities

Rosuvastatin Slows Progression of Carotic Intima-Media Thickness: The METEOR-China Randomized Controlled Study

CALCIUM ANTAGONIST COMBINED WITH STATIN THERAPY ON PLASMA INFLAMMATORY MEDIATORS IN PATIENTS WITH HYPERTENSION AND CAROTID ATHEROSCLEROSIS

Rosuvastatin Inhibits Atherosclerosis Development by Improving Lipid Accumulation and Polarization Conversion of Macrophages via Regulating Autophagy

Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial

Protective effects and the mechanism of Rosuvastatin on type 2 diabetic rats

Effects of valsartan hydrochlorothiazide on carotid intima-media thickness in patients with mild to moderate essential hypertension

[Impact on the Carotid Intima-Medial Thickness and Safety of Rosuvastatin in Chinese Patients with Carotid Atherosclerosis: a Meta-Analysis].

Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial

Effects of Rosuvastatin on Inflammatory Factors and Adiponectin in Patients with Acute Myocardial Infarction

Effects of rosuvastatin on serum asymmetric dimethylarginine levels and incidence of long-term cardiovascular events in patients with hyperlipidaemia and H-type hypertension

Efficacy of simvastatin on carotid atherosclerotic plaque and its effects on serum inflammatory factors and cardiocerebrovascular events in elderly patients